Trevena CEO to Present at the 2011 UBS Global Life Sciences Conference

Sep 15, 2011 8:00am EDT

Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations

Sep 12, 2011 9:00am EDT

Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug

Aug 18, 2011 4:51pm EDT

Trevena Names Arthur Fratamico Chief Business Officer

Apr 11, 2011 8:00am EDT

Trevena Initiates Phase 2 Study of TRV120027 for Acute Heart Failure

Feb 23, 2011 8:00am EST

Trevena CEO to Present at the 2011 BIO CEO and Investor Conference

Feb 11, 2011 11:59am EST

Trevena CEO, Maxine Gowen, Ph.D., Named "Best Executive" at Annual Stevie(R) Awards Ceremony

Nov 18, 2010 7:00am EST

Trevena CEO to Present at the 2010 UBS Global Life Sciences Conference

Sep 16, 2010 4:00pm EDT

Trevena Presents Preclinical Data for TRV120027, a Biased AT1R Ligand, at the 14th Annual Heart Failure Society of America Meeting

Sep 13, 2010 7:00am EDT

Trevena Secures $35 Million in Series B Funding to Progress Portfolio of GPCR Biased Ligands and to Complete Phase 2 Study of TRV120027 for Acute Heart Failure

Jul 14, 2010 7:00am EDT